According to the CDC, approximately six million Americans are living with Alzheimer's disease, but access to experimental, potentially life-saving drugs is limited. For impacted veterans, the Veterans Health Administration is looking for ways to provide that access.
Last year, Biogen, in partnership with Japanese drug company Eisai, announced that the drug called Leqembi showed promise in slowing cognitive decline in Alzaheimer's patients by 27 percent. The VHA announced it will shell out more than $26,000 annually for each veteran on Leqembi. If the FDA grants a full approval by July 6, Medicare and Medicaid services said it would immediately provide broad coverage of the drug to customers.
The experimental treatment received Accelerated Approval by the Food and Drug administration earlier this year. The specific pathway to approval had been introduced by the agency to provide speedier clearance on drugs that treat serious conditions.
Last month the Centers for Medicare and Medicaid Services declined to provide unrestricted coverage of the drug because "there is not yet evidence meeting the criteria for reconsideration."
"This standard differs from the criteria used by the FDA to assess whether medications are safe and effective. We are aware that additional publications may be forthcoming that include information relevant to the questions included in the current NCD," the agency added in its statement.
Riggs Eckelberry, CEO of OriginClear, which manufactures modular clean water systems, provided background on the water safety crisis in the U.S. He also provided best practices on how to test and filter water at home.
The Centers for Disease Control and Prevention is warning of a rare and mysterious deadly fungal infection that is spreading at an alarming rate around the country.
New research shows that exposure to polyfluoroalkyl substances (PFAS), also known as "forever chemicals" can hamper growth and development in children by "altering hormonal and metabolic pathways."
The Centers for Disease Control and Prevention (CDC) on Monday warned that a deadly fungus called Candida auris (C. auris) is spreading at an "alarming rate" in the U.S. healthcare facilities.
Karuna Therapeutics' top-experimental schizophrenia drug significantly reduced symptoms in a late-stage trial but there were concerns that it could cause hypertension in patients.
One of television's most successful writers made a big donation to the Cedars Sinai Medical Center in Los Angeles to help underserved community members gain the skills to become health care professionals.
